5590 results
Refine Your Search
Michael
My journey started in with a lump in my right armpit. After a year of testing, I was diagnosed with Hodgkin lymphoma. I was at the time. After mont…
FDA Approval of New CAR T-Cell Therapy Further Solidifies Immunotherapy as a Mainstay in Cancer Treatment
The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR treatment for adult patients with certain forms of relapsed/refract…
News Release
Patient organizations applaud strong actions to protect people with pre-existing conditions
“President Biden’s actions this week represent a significant first step towards improving access to health coverage for people with conditions. Afte…
LLS Statement on Inauguration Day 2021
February , Our right to vote is the heart of our democracy, as is a free and fair election. The democratic process is critical to our work at The Leu…
FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder
On January , the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly…
News Release
The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills
Patients are now one step closer to breathing a sigh of relief. For too long, they’ve faced the anxiety of knowing that any visit to a healthcare prov…
News Release
Catherine
I was diagnosed in December with blood cancer. I started my treatment in January . I continued treatment until March until I had a Bone Marrow Trans…
Promising Preclinical Combinations of AFM13 and Natural Killer Cells Presented at SITC
Heidelberg, Germany, November , - Affimed N.V. (Nasdaq: AFMD), a company committed to giving patients back their innate ability to fight cancer, an…
Affimed Announces Publication of Final Study Results of AFM13 in Combination with anti-PD-1 therapy in Blood
Heidelberg, Germany, November , – Affimed N.V. (Nasdaq: AFMD), a company committed to giving patients back their innate ability to fight cancer, to…
NexImmune Announces Pricing of Upsized Initial Public Offering
NexImmune, Inc., a biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specifi…
European Commission Approves ELZONRIS for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
FLORENCE, January , – The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the European Commissi…
News Release
Affimed Announces Updated AFM13 Clinical Data Presentation at ASH
Heidelberg, Germany, December , – Affimed N.V. (Nasdaq: AFMD), a company committed to giving patients back their innate ability to fight cancer, to…
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: ASH Update
BOSTON, MA, December , - Verastem, Inc. (Nasdaq:VSTM), a biopharmaceutical company today presented the expansion phase initial results for COPIKTRA® …
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
CAMBRIDGE, Mass., Dec. , - Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters relating …
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December , - FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from the magrolimab Phase 1b trial. Magrolima…
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December , - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced data from the pivotal trial of Yescarta® (axicabtagene …
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at ASH
SAN DIEGO, Dec. , - Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on the development of precision medicines for the treatm…
Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition
Amsterdam, The Netherlands, December , – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a biopharmaceutical …
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at ASH
WATERTOWN, Mass., Dec. , - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver no…
Sutro Biopharma Presents Data for STRO-001 for the Treatment of NHL and AML at ASH
SOUTH SAN FRANCISCO, Calif., Dec. , – Sutro Biopharma, Inc. (NASDAQ: STRO), a drug discovery, development and manufacturing company focused on the a…
BioTheryX Presented Trial in Progress at ASH: A Phase I Trial of BTX-A51 in Patients with AML or High-Risk MDS
Chappaqua, N.Y., December , - BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on inhibition and targ…
Elyssa
My daughter, Elyssa donated her hair for children with cancer only months before she herself was diagnosed with Hodgkins lymphoma. Upon her diagnosis,…
Kendric
In June , I was diagnosed with stage IV Hodgkins lymphoma, but let's backtrack for a minute. In September , I notice that I would (sometimes) experien…
Vonshel
Hi, my name is Von, and back in , I was diagnosed with breast cancer. I didn't want to die, but prayer and God sent me right to the perfect doctor: Dr…
Sandra
I'm a survivor of multiple myeloma and MDS. Now I just want to raise awareness for the cause its seriousness.Having both these diseases is tough, but …